EN
Breast cancer is the most common malignancy among women in Poland and all over the world. Despite the development of modern therapies, cytostatics still play one of the main roles in treatment of this disease. Classic anthracyclines, besides unquestionable efficacy in this disease, have a disadvantageous toxicity profile. Therefore, until now, there has been a limitation in using these drugs in patients with cardiological conditions and in patients who had previously taken anthracyclines. That was the cause for the development of a less toxic form of drug, which is liposomal doxorubicin – being as effective as classic anthracycline it has reduced cardiotoxicity. This article presents the case of a patient with metastatic breast cancer, in whom, after treatment with classic doxorubicin, liposomal form was administered which caused regression of liver metastases. Moreover, during treatment with liposomal doxorubicin, there has been no evidence of heart impairment.